// App-Quantinova.ai

PB0639 : Rivaroxaban 20 mg Oce Daily Decreases Thrombin Generation in Patients with Venous Thromboembolism for up to 24 Hours

Researchers

Presenter

  • J. Kvasnicka

Principal Investigators

  • Z. Krska

  • I. Malikova

  • T. Kvasnicka

Medical Centers

  • General University Hospital VFN, Thrombosis Centre, Prague, Czech Republic

  • General University Hospital VFN, 1.st Dept of Surgery, Prague, Czech Republic

  • General University Hospital VFN, Hematology Laboratory, Prague, Czech Republic

Locations

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Evithrom

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved